BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1053 related articles for article (PubMed ID: 16946130)

  • 1. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice.
    Westerterp M; van der Hoogt CC; de Haan W; Offerman EH; Dallinga-Thie GM; Jukema JW; Havekes LM; Rensen PC
    Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2552-9. PubMed ID: 16946130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholesteryl ester transfer protein (CETP) expression protects against diet induced atherosclerosis in SR-BI deficient mice.
    Harder C; Lau P; Meng A; Whitman SC; McPherson R
    Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):858-64. PubMed ID: 17272756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restoration of high-density lipoprotein levels by cholesteryl ester transfer protein expression in scavenger receptor class B type I (SR-BI) knockout mice does not normalize pathologies associated with SR-BI deficiency.
    Hildebrand RB; Lammers B; Meurs I; Korporaal SJ; De Haan W; Zhao Y; Kruijt JK; Praticò D; Schimmel AW; Holleboom AG; Hoekstra M; Kuivenhoven JA; Van Berkel TJ; Rensen PC; Van Eck M
    Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1439-45. PubMed ID: 20431066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human CETP aggravates atherosclerosis by increasing VLDL-cholesterol rather than by decreasing HDL-cholesterol in APOE*3-Leiden mice.
    de Vries-van der Weij J; Zadelaar S; Toet K; Havekes LM; Kooistra T; Rensen PC
    Atherosclerosis; 2009 Sep; 206(1):153-8. PubMed ID: 19345354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyroid hormone increases plasma cholesteryl ester transfer protein activity and plasma high-density lipoprotein removal rate in transgenic mice.
    Berti JA; Amaral ME; Boschero AC; Nunes VS; Harada LM; Castilho LN; Oliveira HC
    Metabolism; 2001 May; 50(5):530-6. PubMed ID: 11319713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein.
    Marotti KR; Castle CK; Boyle TP; Lin AH; Murray RW; Melchior GW
    Nature; 1993 Jul; 364(6432):73-5. PubMed ID: 8316302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice.
    de Haan W; van der Hoogt CC; Westerterp M; Hoekstra M; Dallinga-Thie GM; Princen HM; Romijn JA; Jukema JW; Havekes LM; Rensen PC
    Atherosclerosis; 2008 Mar; 197(1):57-63. PubMed ID: 17868678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesteryl ester transfer protein directly mediates selective uptake of high density lipoprotein cholesteryl esters by the liver.
    Gauthier A; Lau P; Zha X; Milne R; McPherson R
    Arterioscler Thromb Vasc Biol; 2005 Oct; 25(10):2177-84. PubMed ID: 16123327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Important role for bone marrow-derived cholesteryl ester transfer protein in lipoprotein cholesterol redistribution and atherosclerotic lesion development in LDL receptor knockout mice.
    Van Eck M; Ye D; Hildebrand RB; Kar Kruijt J; de Haan W; Hoekstra M; Rensen PC; Ehnholm C; Jauhiainen M; Van Berkel TJ
    Circ Res; 2007 Mar; 100(5):678-85. PubMed ID: 17293475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein.
    de Vries-van der Weij J; de Haan W; Hu L; Kuif M; Oei HL; van der Hoorn JW; Havekes LM; Princen HM; Romijn JA; Smit JW; Rensen PC
    Endocrinology; 2009 May; 150(5):2368-75. PubMed ID: 19147676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of CETP on the plasma lipoprotein profile in four strains of transgenic mouse.
    Takahashi H; Takahashi A; Maki M; Sasai H; Kamada M
    Biochem Biophys Res Commun; 2001 Apr; 283(1):118-23. PubMed ID: 11322777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.
    van der Hoorn JW; de Haan W; Berbée JF; Havekes LM; Jukema JW; Rensen PC; Princen HM
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):2016-22. PubMed ID: 18669886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-leiden/human C-reactive protein transgenic mice.
    Trion A; de Maat MP; Jukema JW; van der Laarse A; Maas MC; Offerman EH; Havekes LM; Szalai AJ; Princen HM; Emeis JJ
    Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1635-40. PubMed ID: 15920036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A low-saturated-fat, low-cholesterol diet decreases plasma CETP activity and pre beta-HDL formation but does not affect cellular cholesterol efflux to plasma from type 1 diabetic patients.
    De Vries R; Beusekamp BJ; Kerstens MN; Groen AK; Van Tol A; Dullaart RP
    Scand J Clin Lab Invest; 2005; 65(8):729-37. PubMed ID: 16319046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis.
    Klerkx AH; El Harchaoui K; van der Steeg WA; Boekholdt SM; Stroes ES; Kastelein JJ; Kuivenhoven JA
    Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):706-15. PubMed ID: 16439711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein CI overexpression is not a relevant strategy to block cholesteryl ester transfer protein (CETP) activity in CETP transgenic mice.
    Gautier T; Masson D; Jong MC; Pais de Barros JP; Duverneuil L; Le Guern N; Deckert V; Dumont L; Bataille A; Zak Z; Jiang XC; Havekes LM; Lagrost L
    Biochem J; 2005 Jan; 385(Pt 1):189-95. PubMed ID: 15339254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Streptozotocin-induced increase in cholesterol ester transfer protein (CETP) and its reversal by insulin in transgenic mice expressing human CETP.
    Cheema SK; Rashid-Kolvear F
    Can J Physiol Pharmacol; 2003 Oct; 81(10):997-1004. PubMed ID: 14608418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib.
    Clark RW; Sutfin TA; Ruggeri RB; Willauer AT; Sugarman ED; Magnus-Aryitey G; Cosgrove PG; Sand TM; Wester RT; Williams JA; Perlman ME; Bamberger MJ
    Arterioscler Thromb Vasc Biol; 2004 Mar; 24(3):490-7. PubMed ID: 14739125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin.
    de Haan W; de Vries-van der Weij J; van der Hoorn JW; Gautier T; van der Hoogt CC; Westerterp M; Romijn JA; Jukema JW; Havekes LM; Princen HM; Rensen PC
    Circulation; 2008 May; 117(19):2515-22. PubMed ID: 18458167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of type IIA secretory phospholipase A2 inhibits cholesteryl ester transfer protein activity in transgenic mice.
    Hurt-Camejo E; Gautier T; Rosengren B; Dikkers A; Behrendt M; Grass DS; Rader DJ; Tietge UJ
    Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2707-14. PubMed ID: 24115030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.